S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
Log in
NYSE:DGX

Quest Diagnostics Stock Forecast, Price & News

$124.80
+0.47 (+0.38 %)
(As of 11/27/2020 04:24 PM ET)
Add
Compare
Today's Range
$123.81
Now: $124.80
$125.06
50-Day Range
$116.28
MA: $122.64
$128.05
52-Week Range
$73.02
Now: $124.80
$131.81
Volume405,302 shs
Average Volume1.50 million shs
Market Capitalization$16.82 billion
P/E Ratio15.43
Dividend Yield1.80%
Beta1.18
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated has a strategic collaboration with hc1; and strategic relationships with Clinical Genomics Pty Ltd and Anthem Inc. The company was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
Quest Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 1.7Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700
Employees47,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.24 per share
Book Value$47.83 per share

Profitability

Net Income$858 million

Miscellaneous

Market Cap$16.82 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$124.80
+0.47 (+0.38 %)
(As of 11/27/2020 04:24 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock been impacted by Coronavirus (COVID-19)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DGX stock has increased by 25.1% and is now trading at $124.78.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Quest Diagnostics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Quest Diagnostics
.

What stocks does MarketBeat like better than Quest Diagnostics?

Wall Street analysts have given Quest Diagnostics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quest Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Quest Diagnostics
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) released its quarterly earnings results on Thursday, October, 22nd. The medical research company reported $4.31 earnings per share for the quarter, topping analysts' consensus estimates of $3.75 by $0.56. The medical research company had revenue of $2.79 billion for the quarter, compared to analyst estimates of $2.71 billion. Quest Diagnostics had a return on equity of 19.23% and a net margin of 13.22%. The company's quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.76 earnings per share.
View Quest Diagnostics' earnings history
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Wednesday, November 18th. Stockholders of record on Wednesday, January 20th will be paid a dividend of $0.56 per share on Wednesday, February 3rd. This represents a $2.24 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date of this dividend is Tuesday, January 19th.
View Quest Diagnostics' dividend history
.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY20 earnings guidance on Thursday, October, 22nd. The company provided earnings per share guidance of $9.00-$10.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.73. The company issued revenue guidance of $8.8-$9.1 billion, compared to the consensus revenue estimate of $8.78 billion.

What price target have analysts set for DGX?

17 analysts have issued 1-year price objectives for Quest Diagnostics' shares. Their forecasts range from $99.00 to $151.00. On average, they expect Quest Diagnostics' stock price to reach $126.65 in the next year. This suggests a possible upside of 1.5% from the stock's current price.
View analysts' price targets for Quest Diagnostics
.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 63, Pay $2.73M)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 58)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 57, Pay $1.03M)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 45, Pay $976.36k)
  • Mr. Manuel O. Méndez, Sr. VP & Chief Commercial Officer (Age 52, Pay $1.43M)
  • Mr. Michael J. Deppe, VP, Corp. Controller & Chief Accounting Officer (Age 53)
  • Ms. Gabrielle Wolfson, Sr. VP and Chief Information & Digital Officer
  • Mr. Shawn C. Bevec, VP of Investor Relation
  • Mr. Michael E. Prevoznik, Sr. VP & Gen. Counsel (Age 58)
  • Mr. Timothy Sharpe, VP of Compliance

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.42%), State Street Corp (4.96%), Massachusetts Financial Services Co. MA (2.02%), Victory Capital Management Inc. (1.83%), JPMorgan Chase & Co. (1.25%) and Morgan Stanley (0.97%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics
.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Nuveen Asset Management LLC, BlackRock Inc., Acadian Asset Management LLC, Victory Capital Management Inc., AXA S.A., Achmea Investment Management B.V., and First Trust Advisors LP. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Daniel Stanzione, J E Davis, Manner Carrie Eglinton, Michael E Prevoznik, Michael J Deppe, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics
.

Which major investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Morgan Stanley, CI Investments Inc., Allianz Asset Management GmbH, DekaBank Deutsche Girozentrale, Check Capital Management Inc. CA, Clough Capital Partners L P, and MUFG Securities EMEA plc.
View insider buying and selling activity for Quest Diagnostics
.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $124.78.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $16.82 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.